Superpower peptides available for pre-order. Get first access.
Not FDA-approved
Brain & sleep
Semax
Semax is a synthetic peptide approved in Russia but not by the FDA. See how it is thought to work and what the limited human research shows.
- Reviewed by
- William Maish, MD MBA MPH, Clinical Product Lead
- Published
- April 18, 2026
- Last updated
- October 29, 2026
Key takeaway
Semax is a synthetic nootropic peptide developed in Russia, where it is approved for stroke and cognitive conditions, and sold elsewhere on the "research peptide" market for cognition. The human evidence is limited to small, mostly Russian studies not independently replicated to Western standards. As of October 2026 it is still not FDA-approved, but the FDA has granted enforcement discretion allowing it to be compounded by 503A pharmacies while formal rulemaking remains pending.
What is semax?
Semax is a synthetic seven-amino acid peptide based on a fragment of ACTH (adrenocorticotropic hormone), with added amino acids for stability. It was developed by Russian research institutes and is approved in Russia for stroke and cognitive and neurological conditions. Outside Russia it is sold through wellness and "research peptide" channels for cognition and neuroprotection, and it is not an approved medicine in the United States.
How does it work?
Semax is proposed to act as a nootropic and neuroprotectant by increasing levels of nerve-growth signals such as BDNF and NGF and modulating brain chemical systems. These effects are reported mainly in animal and laboratory studies1. This describes the proposed mechanism, separate from demonstrated benefit in people.
Is it FDA-approved?
No. Semax is not approved by the FDA. As neutral regulatory facts: it is approved in Russia for stroke and cognitive indications; and in July 2026 the FDA's Pharmacy Compounding Advisory Committee gave semax a non-binding favorable advisory vote toward allowing it to be compounded under 503A, while FDA staff opposed it citing insufficient evidence2. On October 28, 2026, the FDA granted enforcement discretion5 allowing 503A pharmacies to compound semax (along with five other peptides) while formal rulemaking is still pending. This permits licensed pharmacies to compound semax, but it does not make it an FDA-approved drug, it carries no stated end date, and it does not reflect any new finding that semax is safe or effective.
What does the research show?
There is some human evidence, but of limited quality. Russian studies have reported use in stroke, transient ischemic attack, cognitive disorders, and optic conditions, but the trials are generally:
- Small
- Methodologically weak
- Single-country
- Often developer-affiliated, with little independent replication
An analytical review3 notes these peptides have not completed clinical trials to Western standards. The evidence does not establish efficacy by those standards.
What is the difference between semax and selank?
Semax and selank are both synthetic seven-amino acid peptides developed by Russian research institutes, and the main difference is the natural molecule each is based on and the use each is approved for in Russia, as the table shows:
| Attribute | Semax | Selank |
| Based on | A fragment of the hormone ACTH | Tuftsin, a natural immune-modulating peptide, as a stabilized analog |
| Approved in Russia | For stroke and cognitive and neurological conditions | As an anti-anxiety agent |
| Proposed mechanism | Raises nerve-growth signals such as BDNF and NGF4 | Acts on the brain's enkephalin and GABA systems and on serotonin metabolism |
| U.S. compounding review | Favorable FDA advisory vote in July 2026, which FDA staff opposed; compoundable by 503A pharmacies under FDA enforcement discretion since October 28, 2026 | Not among the peptides reviewed favorably, and not covered by the October 2026 enforcement discretion |
Both mechanism descriptions come mainly from animal and laboratory work, and neither has been shown to produce a benefit in people.
Neither peptide is FDA-approved. Enforcement discretion permits semax to be compounded, but it is not FDA approval, and selank was not among the six peptides covered.
The human evidence for both is limited in the same way: small, mostly Russian studies, often run by the developing institutions and not independently replicated. An analytical review3 notes that such peptides have not completed clinical trials to Western regulatory standards. The evidence does not establish that either one works or that one works better than the other.
Sources: a preclinical study of semax (Glazova et al., Neuropeptides, 2020, DOI: 10.1016/j.npep.2020.1021141) and an analytical review of research peptides (Esposito et al., Drug Testing and Analysis, 2020, DOI: 10.1002/dta.27173), indexed on PubMed; and reporting on the July 2026 FDA advisory committee vote. This document is educational, is not medical advice or a health claim, and is not an offer to sell any product.